Table 1.
Patient Demographics and Baseline Clinical Characteristics.
| Parameter | Candidates for Systemic Therapy Based on IPC guidelines a (n = 2265) |
|---|---|
| Age, mean (SD), years | 48.4 (16.2) |
| Female, n (%) | 1107 (48.9) |
| Race, n (%) | |
| White | 1751 (77.8) |
| Black | 118 (5.2) |
| Asian | 183 (8.1) |
| Other | 198 (8.8) |
| Hispanic ethnicity, n (%) | 303 (13.6) |
| Geographic region, n (%) | |
| Northeast | 659 (29.1) |
| Midwest | 423 (18.7) |
| South | 648 (28.6) |
| West | 304 (13.4) |
| Canada | 231 (10.2) |
| Smoking history, n (%) | |
| Never | 1191 (53.3) |
| Current alcohol use, n (%) | |
| None/occasional | 1126 (53.3) |
| Body mass index, n (%) | |
| Underweight/normal (<18.5-24.9) | 516 (23.3) |
| Overweight (25.0-29.9) | 682 (30.8) |
| Obese (≥30.0) | 1015 (45.9) |
| History of comorbidities, n (%) b | 1058 (46.8) |
| History of anxiety or depression, n (%) | 586 (25.9) |
| PsO duration, mean (SD), years | 9.9 (12.4) |
| PsO disease duration, n (%), years | |
| <10 | 1420 (63.2) |
| 10-20 | 440 (19.6) |
| >20 | 386 (17.2) |
| BSA (% involvement), mean (SD) | 17.4 (15.8) |
| BSA, n (%) | |
| 0%–<3% | 163 (7.2) |
| 3%–10% | 829 (36.6) |
| >10%–100% | 1273 (56.2) |
| PASI score 0-72, mean (SD) | 10.0 (8.4) |
| PASI score, n (%) | |
| 0-5 | 731 (32.3) |
| >5-12 | 877 (38.7) |
| >12-72 | 656 (29.0) |
| IGA score, mean (SD) | 3.0 (0.7) |
| DLQI score >5, n (%) | 1469 (65.1) |
| Initiating therapy, n (%) | |
| Nonbiologic/small molecule | 249 (11.0) |
| Biologic/biosimilar | 2016 (89.0) |
BSA, body surface area; DLQI, Dermatology Life Quality Index; IGA, Investigator’s Global Assessment; PASI, Psoriasis Area and Severity Index; PsO, psoriasis; SD, standard deviation.
aAll patients initiated a systemic therapy, and total sample does not represent all patients with psoriasis.
bIncludes cancer (excluding nonmelanoma skin cancer), cardiovascular disease, cerebrovascular disease, hypertension, hyperlipidemia, diabetes mellitus, hepatic events, gastrointestinal perforation, peptic ulcer, inflammatory bowel disease events, and other gastrointestinal disorders.